Observational studyJournal of Crohn's & colitis2025
Distinct perturbances in metabolic pathways associate with disease progression in inflammatory bowel disease.
Observational study in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Microbiota-Associated Amino Acid Metabolites in Inflammatory Bowel Disease: Emerging Key Players in the Host-Microbe Interface.Microorganisms · 2026Review
- Urinary Organic Acid Profiling by GC-MS Reveals Distinct Metabolic Signatures for Non-Invasive Diagnosis and Disease Activity Monitoring of Inflammatory Bowel Disease.International journal of molecular sciences · 2026Article
- Plasma metabolomic and lipidomic profiling reveals distinct molecular signatures and time-dependent remodeling in ulcerative colitis.BMC gastroenterology · 2026Article
- From Gut Homeostasis to Colorectal Cancer: Spatial and Temporal Reprogramming of Microbial Inosine Signaling.Biomedicines · 2026Review
- Tryptophan pathway metabotypes associate with disease activity and immune-metabolic dysfunction in inflammatory bowel disease.medRxiv : the preprint server for health sciences · 2026Article
- Metabolomics-guided Mechanisms of Mesenchymal Stromal Cell and Exosome Therapies in Chronic Diseases.Stem cell reviews and reports · 2026Review
- Article
- Metabolic Disorders and Inflammatory Bowel Diseases: Unraveling Shared Pathways and Clinical Interactions.Metabolites · 2026Review
- Characteristics of gut microbiota and metabolites in patients with ulcerative colitis with fatigue.World journal of gastroenterology · 2026Article
- Risk factors for readmission in hospitalized patients with inflammatory bowel disease: a retrospective cohort study.American journal of translational research · 2026Article
- Intermittent fasting alleviates ulcerative colitis via lithocholic acid-mediated macrophage reprogramming.Frontiers in nutrition · 2026Article
- Comprehensive analysis of a lipid metabolism-related gene signature for ulcerative colitis.Translational pediatrics · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
BACKGROUND AND
aimsPatients with inflammatory bowel disease (IBD) exhibit distinct shifts in circulating metabolite levels linked to disease activity and phenotype, but associations with disease progression remain unexplored. Our aim was to investigate relationships between circulating metabolites and metabolic pathways with disease progression risk in patients with IBD.
methodsWe performed an observational cohort study using the Mount Sinai Crohn's and Colitis Registry. Follow-up data were retrieved from longitudinal electronic health records. Untargeted metabolomic analysis was performed on baseline serum. Disease progression was defined as new systemic steroid or biological prescriptions, IBD-related hospitalization, or surgery. We used multivariable Cox proportional hazards (CoxPH) regression, L1-regularized CoxPH, and Random Survival Forest models to analyze metabolite associations with disease progression risk.
resultsWe studied 1292 metabolites in 277 patients with ulcerative colitis (UC) and 375 patients with Crohn's disease (CD). Over a median follow-up of 2 years, 57.5% experienced disease progression. In CD, 151 metabolites correlated with disease progression (false discovery rate [FDR] < 0.1): 81 (53.6%) associated with higher risk (enriched in amino acids, purine/pyrimidine metabolism, and bile acids) and 70 (46.4%) with lower risk (enriched in fatty acid oxidation, steroid biosynthesis, tryptophan, and antioxidants). In UC, 84 metabolites associated with disease progression (FDR < 0.1): 29 (34.5%) with increased risk (enriched in sphingolipids, hydrogen sulfide, and tyrosine metabolism) and 55 (65.5%) with decreased risk (enriched in steroid biosynthesis, histidine, and phenylalanine metabolism). Survival models incorporating a combination of metabolomic data and clinical parameters outperformed those based solely on clinical variables, including age, sex, disease location, disease behavior, disease extent, current and prior use of biologics, endoscopic disease activity, surgical history, and perianal disease.
conclusionsSpecific metabolites and pathways are associated with disease progression in IBD, highlighting potential prognostic biomarkers and relevant pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.